Furthermore, based on DSS and PFI survival time-dependent ROC analysis, FOXD3-AS1 expression can predict DSS [1-year (AUC = 0.735), 3-year (AUC = 0.777), and 5-year (AUC = 0.790)] and PFI [1-year (AUC = 0.735), 3-year (AUC = 0.777), and 5-year (AUC = 0.790)] in GBM and LGG patients (Figures 7E,F). Here, FOXD3 is linked to glioblastoma.